Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Coherus BioSciences Company

CHRS
US19249H1032
A12ETZ

Price

0.73
Today +/-
-0.05
Today %
-7.77 %
P

Coherus BioSciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Coherus BioSciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Coherus BioSciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Coherus BioSciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Coherus BioSciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Coherus BioSciences Stock Price History

DateCoherus BioSciences Price
10/28/20240.73 undefined
10/25/20240.78 undefined
10/24/20240.79 undefined
10/23/20240.81 undefined
10/22/20240.86 undefined
10/21/20240.88 undefined
10/18/20240.88 undefined
10/17/20240.85 undefined
10/16/20240.89 undefined
10/15/20240.91 undefined
10/14/20240.94 undefined
10/11/20240.99 undefined
10/10/20240.97 undefined
10/9/20241.00 undefined
10/8/20241.04 undefined
10/7/20241.07 undefined
10/4/20241.04 undefined
10/3/20241.04 undefined
10/2/20241.02 undefined
10/1/20241.02 undefined
9/30/20241.04 undefined

Coherus BioSciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Coherus BioSciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Coherus BioSciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Coherus BioSciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Coherus BioSciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Coherus BioSciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Coherus BioSciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Coherus BioSciences’s growth potential.

Coherus BioSciences Revenue, EBIT and net profit per share

DateCoherus BioSciences RevenueCoherus BioSciences EBITCoherus BioSciences Net Income
2030e1.55 B undefined1.26 B undefined683.35 M undefined
2029e618.29 M undefined1.2 B undefined132.79 M undefined
2028e559.12 M undefined115.83 M undefined111.25 M undefined
2027e510.24 M undefined132.28 M undefined113.99 M undefined
2026e354.61 M undefined1.37 M undefined10.97 M undefined
2025e316.21 M undefined-56.14 M undefined-30.69 M undefined
2024e270.58 M undefined-90.91 M undefined-113.69 M undefined
2023257.24 M undefined-198.3 M undefined-237.89 M undefined
2022211 M undefined-256.9 M undefined-291.8 M undefined
2021326.6 M undefined-263.9 M undefined-287.1 M undefined
2020475.8 M undefined156.3 M undefined132.2 M undefined
2019356.1 M undefined107.8 M undefined89.8 M undefined
20180 undefined-204.4 M undefined-209.3 M undefined
20171.6 M undefined-232.1 M undefined-238.2 M undefined
2016190.1 M undefined-115.9 M undefined-127.3 M undefined
201530 M undefined-219.1 M undefined-223.3 M undefined
201431.1 M undefined-64.7 M undefined-87.1 M undefined
20132.8 M undefined-36 M undefined-53.6 M undefined
20121.9 M undefined-38.5 M undefined-33 M undefined

Coherus BioSciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000.030.030.19000.360.480.330.210.260.270.320.350.510.560.621.55
-100.001,450.00-3.23533.33-99.47--33.43-31.37-35.2821.805.0617.0412.0344.079.6110.55151.13
-------95.2292.2182.5266.8238.13-------
0000000339438269141980000000
-0.04-0.04-0.06-0.22-0.12-0.23-0.20.110.16-0.26-0.26-0.2-0.09-0.0600.130.121.21.26
-3,800.00-1,800.00-206.45-730.00-60.53-23,200.00-30.0632.84-80.67-121.33-77.04-33.33-17.720.2825.8820.57194.0181.31
-33-53-87-223-127-238-20989132-287-291-237-113-3010113111132683
-60.6164.15156.32-43.0587.40-12.18-142.5848.31-317.421.39-18.56-52.32-73.45-133.331,030.00-1.7718.92417.42
32.132.18.237.141.953.16573.283.575.477.694.160000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Coherus BioSciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Coherus BioSciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
14.539.6150.4158.2124.9126.972.4177.7541.2417.2191.7117.75
0000000142157123110260.52
000000000000
0000001.79.844.237.638.862.61
10.15.824.537.634.618.610.413.52524.540.834.76
24.645.4174.9195.8159.5145.584.5343767.4602.3381.3475.63
1.61.74.510.510.812.86.716.520.11614.411.03
000000000000
10000000000000
002.62.62.62.62.62.62.62.65.970.73
009009009009009009009009000943
000.10.92.70.84.845.950.557.479.271.27
1.71.78.114.91717.11565.974.176.999.5153.97
26.347.1183210.7176.5162.699.5408.9841.5679.2480.8629.6
                       
54.754.70000000000.01
000.250.40.560.810.9511.041.151.21.39
-46-99.6-186.7-410-537.3-775.5-984.8-895-762.8-1,049.9-1,341.6-1,579.5
00-0.5-0.4-0.6-0.8-0.3-0.6-0.3-0.3-0.2-0.25
000000000000
9.2-42.466.8-6.220.631.8-38.6105.2280.997.6-137.4-193.43
2.23.38.825.919.715.515.32615.216.211.535.22
3.67.311.224.124.58.517.589129.2148.4126292.53
5.538.931.855.912.24.40.400.7003.3
000000000000
04.20000000.60.71.20.72
11.353.751.8105.956.428.433.2115145.7165.3138.7331.77
0000100.3101.6103.1178.4404.9408.8472.5473.72
000000000001.1
6.136.168.7113.32.52.11.710.410.17.57.116.44
6.136.168.7113.3102.8103.7104.8188.8415416.3479.6491.26
17.489.8120.5219.2159.2132.1138303.8560.7581.6618.3823.03
26.647.4187.3213179.8163.999.4409841.6679.2480.9629.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Coherus BioSciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Coherus BioSciences's financial health and stability.

Assets

Coherus BioSciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Coherus BioSciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Coherus BioSciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Coherus BioSciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-33-53-87-223-127-238-20989132-287-2910
000133332330
000000000000
11412891-159-510-113-3242-79-174
3294539587571828925417643
0000688151718340
000000014100
-1815-23-108-252-200-15928154-37-241-174
-10-2-6-6-40-1-7-1-20
-100-6-6-4-1-12-14-138-166144
0020000-10-7-137-164144
000000000000
010009900732030490
2605411127207105172154974
261013612222620610589223515469
008111100000-1-5-4
000000000000
6251107-332-54104363-123-35339
-20.115-26.7-114.2-259-204.9-160.126.6146.9-38.7-243.1-174.88
000000000000

Coherus BioSciences stock margins

The Coherus BioSciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Coherus BioSciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Coherus BioSciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Coherus BioSciences's sales revenue. A higher gross margin percentage indicates that the Coherus BioSciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Coherus BioSciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Coherus BioSciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Coherus BioSciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Coherus BioSciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Coherus BioSciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Coherus BioSciences Margin History

Coherus BioSciences Gross marginCoherus BioSciences Profit marginCoherus BioSciences EBIT marginCoherus BioSciences Profit margin
2030e38.19 %81.31 %44.03 %
2029e38.19 %193.92 %21.48 %
2028e38.19 %20.72 %19.9 %
2027e38.19 %25.93 %22.34 %
2026e38.19 %0.39 %3.09 %
2025e38.19 %-17.76 %-9.71 %
2024e38.19 %-33.6 %-42.02 %
202338.19 %-77.09 %-92.48 %
202266.82 %-121.75 %-138.29 %
202182.36 %-80.8 %-87.91 %
202092.1 %32.85 %27.78 %
201995.2 %30.27 %25.22 %
201838.19 %0 %0 %
201738.19 %-14,506.25 %-14,887.5 %
201638.19 %-60.97 %-66.96 %
201538.19 %-730.33 %-744.33 %
201438.19 %-208.04 %-280.06 %
201338.19 %-1,285.71 %-1,914.29 %
201238.19 %-2,026.32 %-1,736.84 %

Coherus BioSciences Stock Sales Revenue, EBIT, Earnings per Share

The Coherus BioSciences earnings per share therefore indicates how much revenue Coherus BioSciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Coherus BioSciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Coherus BioSciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Coherus BioSciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Coherus BioSciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Coherus BioSciences Revenue, EBIT and net profit per share

DateCoherus BioSciences Sales per ShareCoherus BioSciences EBIT per shareCoherus BioSciences Earnings per Share
2030e13.47 undefined0 undefined5.93 undefined
2029e5.37 undefined0 undefined1.15 undefined
2028e4.85 undefined0 undefined0.97 undefined
2027e4.43 undefined0 undefined0.99 undefined
2026e3.08 undefined0 undefined0.1 undefined
2025e2.74 undefined0 undefined-0.27 undefined
2024e2.35 undefined0 undefined-0.99 undefined
20232.73 undefined-2.11 undefined-2.53 undefined
20222.72 undefined-3.31 undefined-3.76 undefined
20214.33 undefined-3.5 undefined-3.81 undefined
20205.7 undefined1.87 undefined1.58 undefined
20194.86 undefined1.47 undefined1.23 undefined
20180 undefined-3.14 undefined-3.22 undefined
20170.03 undefined-4.37 undefined-4.49 undefined
20164.54 undefined-2.77 undefined-3.04 undefined
20150.81 undefined-5.91 undefined-6.02 undefined
20143.79 undefined-7.89 undefined-10.62 undefined
20130.09 undefined-1.12 undefined-1.67 undefined
20120.06 undefined-1.2 undefined-1.03 undefined

Coherus BioSciences business model

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences is one of the most popular companies on Eulerpool.com.

Coherus BioSciences SWOT Analysis

Strengths

Coherus BioSciences Inc possesses several key strengths that contribute to its success in the biopharmaceutical industry. These strengths include:

  • A strong portfolio of high-quality biosimilars that provide affordable alternatives to expensive biologic drugs.
  • Strategic partnerships with major pharmaceutical companies, bolstering its distribution network and market reach.
  • A highly skilled and experienced research and development team, enabling the company to develop innovative and effective drugs.
  • An established reputation for delivering products that meet stringent quality and regulatory standards.
  • Effective cost management strategies, allowing the company to maintain competitive pricing and profitability.
  • A robust intellectual property portfolio, providing a strong foundation for innovation and protecting against potential patent disputes.

Weaknesses

Despite its strengths, Coherus BioSciences Inc also faces certain weaknesses that pose challenges to its growth and competitiveness. These weaknesses include:

  • Reliance on a limited number of biosimilar products, making the company vulnerable to market fluctuations and regulatory changes.
  • Dependency on key partnerships for manufacturing and distribution, potentially impacting supply chain reliability.
  • Limited geographic presence, with a significant portion of revenue generated from a few specific markets.

Opportunities

Coherus BioSciences Inc can capitalize on several opportunities within the biopharmaceutical industry, including:

  • Rising demand for affordable biosimilars, as governments and healthcare providers seek cost-effective treatment options.
  • Expanding into new markets and geographies to diversify revenue streams and reduce dependence on specific regions.
  • Potential partnerships and collaborations with other pharmaceutical companies to enhance research capabilities and product offerings.
  • Ongoing advancements in biotechnology and drug delivery systems, opening avenues for innovative product development.

Threats

Coherus BioSciences Inc faces certain threats that may impact its business operations and profitability. These threats include:

  • Intense competition from both established pharmaceutical companies and emerging biosimilar manufacturers.
  • Stringent regulatory requirements and complex approval processes for biosimilar drugs, posing challenges to timely market entry.
  • Potential patent infringements or intellectual property disputes, jeopardizing the company's ability to market certain products.
  • Fluctuations in currency exchange rates and economic conditions, affecting pricing, production costs, and profitability.

Coherus BioSciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Coherus BioSciences historical P/E ratio, EBIT multiple, and P/S ratio

Coherus BioSciences shares outstanding

The number of shares was Coherus BioSciences in 2023 — This indicates how many shares 94.163 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Coherus BioSciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Coherus BioSciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Coherus BioSciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Coherus BioSciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Coherus BioSciences.

Coherus BioSciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.3 -0.14  (52.67 %)2024 Q2
3/31/2024-0.25 -0.32  (-29.76 %)2024 Q1
12/31/2023-0.12 -0.62  (-409.87 %)2023 Q4
9/30/2023-0.28 -0.27  (3.64 %)2023 Q3
6/30/2023-0.49 -0.38  (23.14 %)2023 Q2
3/31/2023-0.58 -0.75  (-28.45 %)2023 Q1
12/31/2022-0.85 -0.6  (29.82 %)2022 Q4
9/30/2022-0.58 -0.96  (-65.12 %)2022 Q3
6/30/2022-0.65 -0.47  (28.05 %)2022 Q2
3/31/2022-0.49 -1  (-103.17 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Coherus BioSciences stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

54

👫 Social

84

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Coherus BioSciences shareholders

%
Name
Stocks
Change
Date
8.97829 % The Vanguard Group, Inc.10,343,893575,28512/31/2023
7.85073 % BlackRock Institutional Trust Company, N.A.9,044,827364,06812/31/2023
6.40666 % Temasek Holdings Pte. Ltd.7,381,116012/31/2023
3.02200 % Barclays Bank PLC3,481,6431,109,36312/31/2023
2.63569 % Kohlberg Kravis Roberts & Co. L.P.3,036,5765004/9/2024
2.46708 % Millennium Management LLC2,842,3192,625,64012/31/2023
2.38174 % Medical Strategy GmbH2,743,998012/31/2023
2.15419 % Pictet Asset Management Ltd.2,481,848602,39212/31/2023
1.96335 % BlackRock Financial Management, Inc.2,261,98084,67912/31/2023
1.83908 % BofA Global Research (US)2,118,804645,22112/31/2023
1
2
3
4
5
...
10

Coherus BioSciences Executives and Management Board

Mr. Dennis Lanfear67
Coherus BioSciences Chairman of the Board, President, Chief Executive Officer (since 2010)
Compensation 6.87 M
Mr. McDavid Stilwell52
Coherus BioSciences Chief Financial Officer
Compensation 2.09 M
Dr. Lee Newcomer70
Coherus BioSciences Independent Director
Compensation 442,601
Mr. Charlie Newton52
Coherus BioSciences Independent Director
Compensation 350,910
Mr. Mats Wahlstrom69
Coherus BioSciences Lead Independent Director
Compensation 328,690
1
2
3

Coherus BioSciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Avid Bioservices Stock
Avid Bioservices
SupplierCustomer0,820,950,960,960,82-0,25
Innovent Biologics Stock
Innovent Biologics
SupplierCustomer0,530,790,740,890,660,38
Amgen Stock
Amgen
SupplierCustomer0,23-0,79-0,25-0,67-0,77-0,19
Pfizer Stock
Pfizer
SupplierCustomer0,180,84-0,030,31-0,24-0,54
Shanghai Junshi Biosciences H Stock
Shanghai Junshi Biosciences H
SupplierCustomer0,09-0,15-0,17-0,63-0,52-0,24
AbbVie Stock
AbbVie
SupplierCustomer-0,080,67-0,31-0,82-0,80-0,82
Model N Stock
Model N
SupplierCustomer-0,190,790,590,800,650,63
1

Most common questions regarding Coherus BioSciences

What values and corporate philosophy does Coherus BioSciences represent?

Coherus BioSciences Inc represents a set of core values and a corporate philosophy that guide its operations. The company is committed to bringing high-quality and cost-effective biosimilar therapies to patients. With a focus on innovation, Coherus BioSciences aims to improve access to important treatments and enhance patients' quality of life. By fostering a collaborative working environment, the company encourages creativity and teamwork among its employees. Coherus BioSciences also prioritizes integrity, transparency, and ethical behavior in its business practices. Through its dedication to patients, innovation, and values-driven approach, Coherus BioSciences Inc strives to make a positive impact in the pharmaceutical industry.

In which countries and regions is Coherus BioSciences primarily present?

Coherus BioSciences Inc is primarily present in the United States, with its headquarters located in Redwood City, California. As a leading global biosimilar company, Coherus BioSciences Inc focuses on developing and commercializing high-quality therapeutics that expand patient access to important medicines. While the company's primary presence is in the US, it also possesses a growing international footprint. With a commitment to improving patient lives worldwide, Coherus BioSciences Inc continues to expand its reach and impact in various countries and regions to provide innovative treatment options for a range of medical conditions.

What significant milestones has the company Coherus BioSciences achieved?

Some significant milestones achieved by Coherus BioSciences Inc include the successful completion of clinical trials for their biosimilar products and securing regulatory approvals for their medications. The company has also expanded its portfolio through partnerships and collaborations with other pharmaceutical companies. Furthermore, Coherus BioSciences Inc has achieved reimbursement agreements for their biosimilar products, ensuring broader access to affordable treatments. These milestones demonstrate the company's commitment to advancing biosimilar therapies and improving patient access to high-quality, cost-effective medications.

What is the history and background of the company Coherus BioSciences?

Coherus BioSciences Inc, founded in 2010, is a leading biotechnology company focused on the development and commercialization of high-quality biosimilar therapeutics. Headquartered in Redwood City, California, Coherus is dedicated to expanding patient access to essential and cost-effective treatments. With expertise in drug development, manufacturing, and commercialization, the company has successfully launched biosimilar products in multiple therapeutic areas. Coherus is committed to improving patient lives by providing affordable and reliable medications. It is recognized as a key player in the global biopharmaceutical industry, delivering innovative solutions to meet healthcare challenges.

Who are the main competitors of Coherus BioSciences in the market?

Some of the main competitors of Coherus BioSciences Inc in the market include big players such as Amgen Inc., Pfizer Inc., and Novartis AG. These companies also operate within the pharmaceutical sector and compete in the development and commercialization of biosimilar drugs. While Coherus BioSciences Inc aims to offer cost-effective alternatives to expensive biologic drugs, it faces competition from these industry giants who also have significant market shares and resources. Being aware of the competitive landscape is important for investors and stakeholders to understand the dynamics within the market for Coherus BioSciences Inc.

In which industries is Coherus BioSciences primarily active?

Coherus BioSciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Coherus BioSciences?

The business model of Coherus BioSciences Inc. is focused on developing and commercializing high-quality biosimilar therapeutics. As a leading global biosimilar company, Coherus is dedicated to providing patients with access to affordable treatment options. By leveraging their expertise in biologic drug development, Coherus aims to develop biosimilars that are highly similar to reference products in terms of safety, efficacy, and quality. This business model allows Coherus to contribute to the reduction of healthcare costs while maintaining a commitment to improving patient outcomes.

What is the P/E ratio of Coherus BioSciences 2024?

The Coherus BioSciences P/E ratio is -0.6.

What is the P/S ratio of Coherus BioSciences 2024?

The Coherus BioSciences P/S ratio is 0.25.

What is the Quality Investing of Coherus BioSciences?

The Quality Investing for Coherus BioSciences is 4/10.

What is the revenue of Coherus BioSciences 2024?

The expected Coherus BioSciences revenue is 270.58 M USD.

How high is the profit of Coherus BioSciences 2024?

The expected Coherus BioSciences profit is -113.69 M USD.

What is the business model of Coherus BioSciences

Coherus BioSciences Inc is an emerging biotechnology company specializing in the development and commercialization of high-quality biosimilars. The company's business model is based on providing cost-effective and accessible treatment options for patients suffering from cancer, inflammatory diseases, and other serious illnesses. Coherus BioSciences is headquartered in Redwood City, California, and is listed on the NASDAQ Global Market under the ticker symbol "CHRS". Coherus BioSciences has an extensive pipeline of biosimilars in various stages of development. A biosimilar is a biological medicine that has similar properties to an already approved biological medicine. Biosimilars can generally be produced and offered at a lower cost than the original product. Coherus BioSciences has already successfully launched some biosimilars on the market, such as the Adalimumab biosimilar UDENYCA® for the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences' business model also includes collaborations with other major pharmaceutical companies such as Pfizer and Daiichi-Sankyo. These partnerships enable Coherus BioSciences to access resources and technologies to accelerate and improve the development of biosimilars. Through its partnerships, Coherus BioSciences is also able to expand its global presence in the market and penetrate into new geographical regions. The company has an extensive product pipeline, which includes several biosimilars in various stages of development. Some of the key products currently being developed by Coherus BioSciences are biosimilars of Pegfilgrastim, Bevacizumab, and Etanercept. Pegfilgrastim is used for the prevention of infections in patients receiving chemotherapy, while Bevacizumab is used for the treatment of various types of cancer. Etanercept is used for the treatment of rheumatoid arthritis and psoriasis. Coherus BioSciences also has a business model focused on expanding its operations into other therapeutic areas such as cancer and inflammatory diseases. The company also plans to expand into new geographical regions to strengthen its global presence and increase its revenues and profits. In 2021, the company expanded its presence in the European market with the launch of UDENYCA® and another biosimilar as part of its partnership with Baxalta. In summary, Coherus BioSciences' business model is aimed at providing cost-effective treatment options for patients with serious illnesses. The company specializes in the development and sale of biosimilars and has an extensive product pipeline in various stages of development. Coherus BioSciences also works closely with major pharmaceutical companies to expand its operations and strengthen its global presence.

What is the Coherus BioSciences dividend?

Coherus BioSciences pays a dividend of 0 USD distributed over payouts per year.

How often does Coherus BioSciences pay dividends?

The dividend cannot currently be calculated for Coherus BioSciences or the company does not pay out a dividend.

What is the Coherus BioSciences ISIN?

The ISIN of Coherus BioSciences is US19249H1032.

What is the Coherus BioSciences WKN?

The WKN of Coherus BioSciences is A12ETZ.

What is the Coherus BioSciences ticker?

The ticker of Coherus BioSciences is CHRS.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

All fundamentals about Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.